ClinicalTrials.gg
Active, not recruitingNCT07052032Updated Sep 3, 2026

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

A Phase 1 interventional study of CND261 in Rheumatoid Arthritis, sponsored by Candid Therapeutics. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Candid Therapeutics (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies in Arthritis, Rheumatoid by UCB S.A. — 1 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · UCB S.A..

Planned enrollment
27th of 34
47 · median 207
Started
2025
the only one that year
Phase 1
6 of 42
1 open now
Registered
41st of 42
by date

Among the 42 studies in Arthritis, Rheumatoid by UCB S.A., this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 1, and was the 41st registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 42 studies in Arthritis, Rheumatoid by UCB S.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Arthritis, Rheumatoid by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.

Read the detailed description

This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND261 in patients with seropositive rheumatoid arthritis. The study consists of 2 parts: a dose-escalation part and an open-label expansion. Patients will be followed until Week 52.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old
  2. Diagnosis of adult-onset RA
  3. Class I-III RA
  4. Moderately to severely active RA
  5. Inadequate treatment response as defined in the protocol
  6. Stable use of any concomitant therapies

Exclusion criteria

Exclusion Criteria:

  1. Inadequate clinical laboratory parameters at Screening
  2. Active infection
  3. Receipt of or inability to discontinue any excluded therapies
  4. Receipt of within 4 weeks
  5. Presence of any concomitant disease
  6. Active or known history of catastrophic anti-phospholipid syndrome
  7. APS or thrombotic event not adequately controlled by anticoagulation therapy
  8. History of progressive multifocal leukoencephalopathy
  9. Central nervous system disease
  10. Presence of 1 or more significant concurrent medical conditions
  11. Have a diagnosis or history of malignant disease within 5 years
  12. Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair ability to receive planned treatment or to understand
  13. History of or planned organ transplant and/or or allogeneic hematopoietic stem cell transplantation
  14. Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study
  15. Women who are pregnant or breastfeeding
  16. Patients who do not agree to the use of highly effective as defined by the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    CND261

    Biological: CND261

Interventions

  • BiologicalCND261

    CND261 will be dosed according to the assigned cohort

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events through end of study

    Time frame: Baseline to Month 12

  2. Changes from baseline in vital signs through end of study

    Time frame: Baseline to Month 12

  3. Changes from baseline in ECG parameters through end of study: PR interval

    Time frame: Baseline to Month 12

  4. Changes from baseline in ECG parameters through end of study: QRS interval

    Time frame: Baseline to Month 12

  5. Changes from baseline in ECG parameters through end of study: QTcF interval

    Time frame: Baseline to Month 12

  6. Changes from baseline in safety laboratory assessments through end of study

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Pharmacokinetic (PK) concentration-time profiles for CND261

    Time frame: Baseline to Month 12

  2. PK parameters for CND261: maximum concentration

    Time frame: Baseline to Month 12

  3. PK parameters for CND261: time of maximum concentration

    Time frame: Baseline to Month 12

  4. PK parameters for CND261: area under the concentration-time curve

    Time frame: Baseline to Month 12

  5. PK parameters for CND261: clearance

    Time frame: Baseline to Month 12

  6. PK parameters for CND261: volume of distribution

    Time frame: Baseline to Month 12

  7. PK parameters for CND261: half-life

    Time frame: Baseline to Month 12

07

Study locations

2 sites
  • Candid Clinical Site
    Chisinau, Moldova
  • Candid Clinical Site
    Kyiv, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 23 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jul 4, 2025
StartActual
Jun 16, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052032
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Jun 16, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion